COVID-19: immunopathogenesis and Immunotherapeutics.
Signal Transduct Target Ther
; 5(1): 128, 2020 07 25.
Article
in English
| MEDLINE | ID: covidwho-680767
ABSTRACT
The recent novel coronavirus disease (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is seeing a rapid increase in infected patients worldwide. The host immune response to SARS-CoV-2 appears to play a critical role in disease pathogenesis and clinical manifestations. SARS-CoV-2 not only activates antiviral immune responses, but can also cause uncontrolled inflammatory responses characterized by marked pro-inflammatory cytokine release in patients with severe COVID-19, leading to lymphopenia, lymphocyte dysfunction, and granulocyte and monocyte abnormalities. These SARS-CoV-2-induced immune abnormalities may lead to infections by microorganisms, septic shock, and severe multiple organ dysfunction. Therefore, mechanisms underlying immune abnormalities in patients with COVID-19 must be elucidated to guide clinical management of the disease. Moreover, rational management of the immune responses to SARS-CoV-2, which includes enhancing anti-viral immunity while inhibiting systemic inflammation, may be key to successful treatment. In this review, we discuss the immunopathology of COVID-19, its potential mechanisms, and clinical implications to aid the development of new therapeutic strategies against COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Shock, Septic
/
Disease Outbreaks
/
Coronavirus Infections
/
Pandemics
/
Betacoronavirus
/
Immunity, Innate
/
Immunotherapy
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Signal Transduct Target Ther
Year:
2020
Document Type:
Article
Affiliation country:
S41392-020-00243-2
Similar
MEDLINE
...
LILACS
LIS